top of page

Mestastop Solutions and Ectica Technologies participate in the Swiss Biotech Days 2024

MESTASTOP SOLUTIONS Ltd. is excited to be invited to the Swiss Biotech Days 2024, a pivotal event gathering biotech and pharma leaders annually in Basel, Switzerland. Scheduled for April 22nd and 23rd, this event at the Congress Center Basel holds significant importance within the European industry landscape.


This year, we are thrilled to welcome our partner, Mestastop Solutions Ltd., to Switzerland. Mestastop is an emerging Indian biotech firm with operational hubs in Bangalore, India, and New Jersey, USA. The company was established with a mission to combat metastasis and enhance outcomes for cancer patients. Leveraging proprietary translational in vitro and ex vivo platforms, the Mestastop team delves into metastasis biology to discover novel therapeutic avenues, and to repurpose existing therapies. By isolating patient primary tumor samples, Mestastop identifies distinct phenotypes serving as markers of metastatic cells.

Their flagship METASSAY® platform is a robust in vitro/ex vivo phenotypic assay system that dissects the intricate biology of metastasis. Complementing this, METVIVO® offers a rapid and reliable metastasis animal model capable of discerning anti-proliferative from anti-metastatic compound activity. Furthermore, METSCAN®, their translational platform, evaluates functional attributes of patient-derived primary tumor cells, facilitating target identification, characterization, and translational drug discovery. (Learn more about Mestastop’s platforms)



Reproduced with permission of Mestastop


ABOUT THE MESTASTOP SOLUTIONS AND ECTICA TECHNOLOGIES COLLABORATION


Ectica is keen to strenghten Mestastop’s platform with its cutting-edge technology. Both teams have collaborated extensively with the shared objective of dissecting the 3D invasive properties of cancer cell lines and patient primary tumor cells. Recently, Chinmaya Amarakanth, Senior Scientist at Mestastop, presented their joint work at the 3D Cell Culture conference in Mumbai, India. The presentation, titled “A translationally relevant, 3D spheroid-based medium throughput screening system that differentiates among cells with variable plasticity” showcased their high-content screening (HCS)-based assay and will be proposed in April in Basel. This assay, utilizing quantitative data analysis on images of 3D multi-spheroid structures developed in synthetic hydrogel multiwell plates, assesses spheroid size, shape, and internal organization, yielding a morphological response to compound treatments. The inhibition data, represented by spheroid size, is pivotal in determining the efficacy of chemotherapies and is instrumental in studying the distinct functional responses of metastatic and non-metastatic cells. In the long term, the teams aim to incorporate stromal cells, such as cancer-associated fibroblasts (CAFs), to conduct drug testing on advanced co-culture systems.




Download the full poster here:


2024_A translationally relevant, 3D spheroid-based medium throughput screening system that
.
Download • 5.35MB


MEET WITH US

Mestastop is visiting Switzerland represented by the founder and Director, Dr. Arnab Roy Chowdhury, to fortify collaborations with biopharma companies and technology providers across Europe. Arnab is incredibly excited to present the opportunity of using Ectica plates on the Mestastop platforms with patient sample access, generating translational relevance like never before. If you wish to engage with Mestastop and Ectica at the Swiss Biotech Days, kindly reach out to us via email at info@ectica-technologies.com or utilize the online partnering system, “Hello Partnering,” after registering here.



ABOUT ECTICA TECHNOLOGIES


Established in 2015 as a spin-off from the University (Hospital) Zurich and ETH Zurich, Ectica Technologies is a Swiss life science company specializing in the development and production of hydrogel-based in vitro and ex vivo human organotypic models. Ectica aims to contribute to pre-clinical research and drug discovery with advanced human models, enhancing the efficiency of the selection of anti-fibrotic and anti-cancer compounds and reducing the industry’s reliance on animal models.




Comments


bottom of page